Brain Hemorrhage - Pipeline Insight, 2024

This “Brain Hemorrhage - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Brain Hemorrhage pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Brain Hemorrhage Understanding

Brain Hemorrhage: Overview

A brain hemorrhage refers to bleeding in the brain. This medical condition is also known as a brain bleed or an intracranial hemorrhage. It is a medical emergency that requires immediate treatment. The skull surrounds the brain, and any leaking blood from a hemorrhage can cause compression and damage to the brain tissues. The effects of a brain hemorrhage vary within different age groups. Brain hemorrhages are most likely to occur in older adults. A brain hemorrhage can cause a range of different symptoms. These symptoms may include sudden tingling, weakness, numbness, or paralysis of the face, arm, or leg. This is most likely to occur on one side of the body only. Complications often arise from a brain hemorrhage. The bleeding prevents the nerve cells from communicating with other parts of the body and resuming normal function. Brain bleed treatments depend on the size of the hemorrhage, its location in the brain, and the amount of swelling it causes.

Brain Hemorrhage - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Brain Hemorrhage pipeline landscape is provided which includes the disease overview and Brain Hemorrhage treatment guidelines. The assessment part of the report embraces, in depth Brain Hemorrhage commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Brain Hemorrhage collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Brain Hemorrhage.
• In the coming years, the Brain Hemorrhage market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Brain Hemorrhage R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Brain Hemorrhage treatment market. Several potential therapies for Brain Hemorrhage are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Brain Hemorrhage market size in the coming years.
• This in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Brain Hemorrhage) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Brain Hemorrhage Emerging Drugs Chapters

This segment of the Brain Hemorrhage report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Brain Hemorrhage Emerging Drugs

CN 105: AegisCNCN 105, a small five amino acid apolipoprotein E (apoE)-mimetic peptide, is being developed by AegisCN (formerly CereNova), for the treatment of Cerebral haemorrhage. Currently, it is in Phase II stage of clinical trial evaluation for the treatment of patients suffering from cerebral haemorrhage.

NP10679: NeurOp, Inc.NeurOp is developing NP10679 as a subunit-specific NMDA receptor inhibitor for CNS disorders. NMDA receptors are activated by the neurotransmitter glutamate, the predominant excitatory transmitter in the brain. Several neurological disorders, including pain, treatment-resistant depression and brain damage resulting from acute brain injury, such as stroke or SAH, are associated with overactivity of these receptors. NP10679 is selective for a specific NMDA subtype, GluN2B, and has increased potency in acidic conditions. Its enhanced selectivity and disease context-dependent target engagement may provide neuroprotection with fewer negative side effects than currently available NMDA inhibitors.

Brain Hemorrhage: Therapeutic Assessment

This segment of the report provides insights about the different Brain Hemorrhage drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Brain Hemorrhage

There are approx. 10+ key companies which are developing the therapies for Brain Hemorrhage. The companies which have their Brain Hemorrhage drug candidates in the most advanced stage, i.e. phase II include, AegisCN.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Brain Hemorrhage pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Brain Hemorrhage: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Brain Hemorrhage therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Brain Hemorrhage drugs.

Brain Hemorrhage Report Insights

• Brain Hemorrhage Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Brain Hemorrhage Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Brain Hemorrhage drugs?
• How many Brain Hemorrhage drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Brain Hemorrhage?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Brain Hemorrhage therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Brain Hemorrhage and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Jiangsu Simcere Pharmaceutical Co., Ltd.
• AegisCN
• NeurOp, Inc.
• Capricor Therapeutics
• aptaTargets
• Novartis Pharmaceuticals
• Evgen Pharma
• BIT pharma
• Acasti Pharma Inc.

Key Products

• Edaravone Dexborneol
• CN 105
• NP10679
• Cardiosphere-Derived Exosomes
• ApTOLL
• BAF312
• SFX-01
• Nicardipine
• GTX-104

This product will be delivered within 2 business days.